Abstract:SUMMARY The human immunodeficiency virus (HIV) epidemic remains a formidable global health concern, with 39 million people living with the virus and 1.3 million new infections reported in 2022. Despite anti-retroviral therapy’s effectiveness in pre-exposure prophylaxis, its global adoption is limited. Broadly neutralizing antibodies (bNAbs) offer an alternative strategy for HIV prevention through passive immunization. Historically, passive immunization has been efficacious in the treatment of various diseases ranging from oncology to infectious diseases. Early clinical trials suggest bNAbs are safe, tolerable, and capable of reducing HIV RNA levels. Although challenges such as bNAb resistance have been noted in phase I trials, ongoing research aims to assess the additive or synergistic benefits of combining multiple bNAbs. Researchers are exploring bispecific and trispecific antibodies, and fragment crystallizable region modifications to augment antibody efficacy and half-life. Moreover, the potential of other antibody isotypes like IgG3 and IgA is under investigation. While promising, the application of bNAbs faces economic and logistical barriers. High manufacturing costs, particularly in resource-limited settings, and logistical challenges like cold-chain requirements pose obstacles. Preliminary studies suggest cost-effectiveness, although this is contingent on various factors like efficacy and distribution. Technological advancements and strategic partnerships may mitigate some challenges, but issues like molecular aggregation remain. The World Health Organization has provided preferred product characteristics for bNAbs, focusing on optimizing their efficacy, safety, and accessibility. The integration of bNAbs in HIV prophylaxis necessitates a multi-faceted approach, considering economic, logistical, and scientific variables. This review comprehensively covers the historical context, current advancements, and future avenues of bNAbs in HIV prevention.

Broadly neutralizing antibodies and vaccine design against HIV-1 infection

Broadly neutralizing antibodies against human immunodeficiency virus type 1(HIV-1) and rational design of HIV-1 vaccines

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies.

Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies

HIV-1 Antibodies from Infection and Vaccination: Insights for Guiding Vaccine Design

Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention

Antibody-based Candidate Therapeutics Against HIV-1: Implications for Virus Eradication and Vaccine Design

Antibody‐virus Co‐evolution in HIV Infection: Paths for HIV Vaccine Development

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

[Advances in the Immunogenic Design of HIV-1 Vaccine].

Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

Identification and specificity of broadly neutralizing antibodies against HIV

VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design

Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Small-molecule HIV-1 Entry Inhibitors Targeting the Epitopes of Broadly Neutralizing Antibodies

Progress in HIV-1 Vaccine Development.